Insights on Clinical Trials

  1. Commercializing Rare Disease Treatment With Near Real-Time Alerts 5/16/2025

    How did Quest help a leading pharmaceutical company overcome the data latency challenges associated with traditional EHR when recruiting eligible patients for a rare blood disorder drug?

  2. Infectious Diseases - Global Clinical Trial Landscape (2025) 5/14/2025

    The global infectious disease clinical trial landscape has rapidly expanded between 2020 and 2024, driven by the urgency of emerging threats, technological innovation, and evolving regulatory frameworks.

  3. Obesity - Global Clinical Trial Landscape (2025) 5/14/2025

    This report analyzes the current state of global and Asia-Pacific obesity trials, highlighting regional trends, sponsor activity, and preferred endpoints.

  4. Atsena Therapeutics Advances Gene Therapy For XLRS 5/13/2025

    Atsena Therapeutics exemplifies the field’s growing shift toward non-oncology indications with its targeted gene therapy for X-linked retinoschisis, a rare inherited retinal disorder with no approved treatments.

  5. 3 Strategies For A Successful Journey Toward Cell And Gene Therapy Commercialization 5/13/2025

    CTMC's Amy Hay provides 3 recommendations for teams developing cell and gene therapies, from clinical research through commercialization.

  6. Clinical Trial Participation: Solving The Awareness Challenge 5/12/2025

    Recruiting participants for clinical trials is a persistent challenge, but new digital platforms are helping to address the challenges of connecting potential participants in time a timely manner.

  7. Continuing Your Research Mission -- Even As Budgets Tighten 5/12/2025

    Amid growing uncertainty in clinical research funding, including proposed budget cuts from the NIH that threaten indirect support for essential infrastructure, OpenClinica remains a steadfast partner to researchers.

  8. Small Cell Lung Cancer- Global Clinical Trial Landscape (2025) 5/9/2025

    Historically dominated by chemotherapy and radiation, the treatment paradigm for small cell lung cancer (SCLC) is evolving in response to limited survival benefits and high relapse rates.

  9. Understanding The Impact Of An RMP On Patient Risks Using Relational Risk Analysis 5/5/2025

    Using relational risk analysis, let's take a closer look at risk management plans for identifying and managing adverse reactions for administering a new therapy to a patient.

  10. Addressing Market Access Challenges As CGTs Expand To Larger Patient Populations 5/1/2025

    Navigating market access for advanced therapies requires new strategies. Explore ways to boost payer understanding, innovate pricing, and adapt treatment settings as these therapies expand.